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106Objective: To determine the incidence, risk factors, and outcomes after early, unplanned intervention on
systemic-to-pulmonary artery shunts in neonates.
Methods:We retrospectively studied all neonates undergoing systemic-to-pulmonary artery shunt placement at
The Children’s Hospital of Philadelphia between September 1, 2002, and May 1, 2005. Patients requiring trans-
catheter or surgical systemic-to-pulmonary artery shunt intervention before dischargewere compared with those
not undergoing shunt intervention.
Results:A total of 206 patients underwent shunt placement. Diagnoses included hypoplastic left heart syndrome
(62.1%), pulmonary atresia (15%), tricuspid atresia (4.9%), tetralogy of Fallot (2.4%), and other lesions with
obstruction to systemic (10.7%) or pulmonary blood flow (4.9%). Twenty-one interventions occurred in 20 pa-
tients (9.7%). Risk factors for intervention included heterotaxy syndrome (P ¼ .04), congenital abnormality
(P ¼ .04), and a trend toward lower birthweight. In patients with a modified Blalock–Taussig shunt, similar
risk factors were identified and the incidence of intervention decreased with increasing shunt size. In-hospital
mortality was 30% (6/20) for the cases and 8.1% (15/186) for the nonintervention group (P ¼ .02). Long-
term survival was significantly lower in patients requiring intervention (P¼ .002). This group also had a higher
incidence of infections (P<.001) and extracorporeal membrane oxygenation (P<.001), and longer hospital stay
(P ¼ .001).
Conclusions: In neonates undergoing systemic-to-pulmonary artery shunt placement, approximately 10%
underwent shunt intervention before discharge. Some factors, such as low birthweight, shunt size, noncardiac
congenital abnormalities, and heterotaxy syndrome, may help identify patients at risk. Patients undergoing
intervention experienced increased morbidity and mortality. (J Thorac Cardiovasc Surg 2011;142:106-12)The systemic-to-pulmonary artery (S-PA) shunt is widely
used in the surgical palliation of various forms of congenital
heart disease (CHD). After placement, maintenance of
shunt patency and freedom from mechanical distortion of
the shunt and pulmonary arteries are imperative because
pulmonary blood flow is exclusively shunt-dependent in
the absence of native or collateral pulmonary blood flow.
Despite improvements in operative mortality in recent
decades1 that parallel increased survival in children with
CHD, patients with shunt-dependent pulmonary blood
flow continue to experience significant early and late mor-
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The Journal of Thoracic and Cardiovascular Surgplacement and before further surgical interventions (inter-
stage mortality) continues to occur in 10% to 15% of
infants.2,3 Postoperative mortality has been ascribed to
many potential factors, with acute or chronic shunt
occlusion from shunt thrombosis, shunt stenosis, or
downstream pulmonary artery distortion likely playing
a large role in postoperative attrition. Measures that have
been proposed to detect or prevent events leading to
interstage mortality include home monitoring with pulse
oximetry,6 postoperative heparin administration,7 and aspi-
rin.8 A recent prospective multicenter, multinational trial
demonstrated that postoperative aspirin in patients with
S-PA shunts decreased the risk of shunt thrombosis and
death.4
Morbidity and mortality related to S-PA shunts may be in
part affected by shunt type. In children with hypoplastic left
heart syndrome (HLHS) undergoing stage I palliation, the
relative incidence of shunt intervention between modified
Blalock–Taussig shunts (mBTS) and right ventricle-
to-pulmonary artery (RV-PA) shunts has been studied exten-
sively. Previous work from our center9,10 demonstrated an
increased incidence of unplanned shunt interventions in
patients receiving an RV-PA shunt. Similarly, in the ran-
domized, multicenter single ventricle reconstruction trial
comparing outcomes in children with HLHS and variantsery c July 2011
Abbreviations and Acronyms
BUN ¼ blood urea nitrogen
CHD ¼ congenital heart disease
ECMO ¼ extracorporeal membrane oxygenation
HLHS ¼ hypoplastic left heart syndrome
mBTS ¼ modified Blalock–Taussig shunt
RV-PA ¼ right ventricle-to-pulmonary artery
S-PA ¼ systemic-to-pulmonary artery
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placed at the Norwood procedure, the incidence of un-
planned cardiovascular interventions in the first 12 months
after trial enrollment was higher in the group receiving an
RV-PA shunt. Early survival was greater with the RV-PA
shunt group, but survival between groups was not signifi-
cantly different in late follow-up.11
Although many cases of S-PA shunt dysfunction only
come to clinical attention after hospital discharge and thus
fall into the interstage period, we have noted that a sizeable
proportion of patients palliated with S-PA shunts manifest
evidence of shunt dysfunction during their initial hospitali-
zation. The incidence of and risk factors for such ‘‘early’’
S-PA shunt dysfunction in CHD have not been well defined.
The primary purpose of this study was to describe the inci-
dence of shunt dysfunction and identify risk factors for
early surgical or transcatheter shunt intervention in patients
with CHD palliated with S-PA shunts.C
H
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After institutional review board approval and waiver of informed con-
sent, a retrospective cohort study of all neonates (30 days of age) under-
going S-PA shunt placement at The Children’s Hospital of Philadelphia
between September 1, 2002, and May 1, 2005, was performed (n ¼ 206).
For the purposes of this study, S-PA shunts were defined as one of the fol-
lowing surgically placed connections between the systemic and pulmonary
circulations: mBTS, central shunts, and RV-PA shunts as part of the Nor-
wood procedure for HLHS and variants. The patient population was iden-
tified through review of the cardiac intensive care unit, cardiology, and
surgical databases. We obtained information regarding the postoperative
course, morbidity, and mortality by review of the hospital medical record,
operative reports, cardiac catheterization reports, echocardiogram reports,
and contact with referring physicians.
Four surgeons were active during the time period of this study. For pa-
tients with HLHS and other single ventricle lesions with obstructed sys-
temic blood flow undergoing stage I palliation, operative technique and
general institutional standards of postoperative care have been described.9
The type of shunt placed was at the discretion of the attending surgeon. The
ductus arteriosus was uniformly ligated in lesions with ductal-dependent
systemic blood flow, and with few exceptions was ligated in lesions with
ductal-dependent pulmonary blood flow. Patients evaluated in this study
were not enrolled in the multicenter single ventricle reconstruction
trial.11,12 After initial shunt placement, patients undergoing a separately
performed surgical or transcatheter shunt intervention before hospital
discharge were identified (intervention group) and compared withThe Journal of Thoracic and Caneonates undergoing S-PA shunt placement during the same time period
who did not undergo in-hospital intervention (nonintervention group). Pa-
tients transferred from The Children’s Hospital of Philadelphia to another
inpatient medical facility who returned for intervention were included in
the intervention group.We excluded patients who underwent intraoperative
shunt revision during the initial shunt procedure or shunt intervention after
hospital discharge, as well as those with suspected shunt dysfunction who
did not undergo an intervention procedure.
All patients were characterized by gender, gestational age, birthweight,
presence of significant noncardiac congenital abnormalities (including
identified genetic syndromes), presence of heterotaxy syndrome, underly-
ing cardiac diagnosis, and age at S-PA shunt placement. Prematurity was
defined categorically as a gestational age at birth of less than 37 completed
weeks of gestation. Low birthweight was defined categorically as less than
2.5 kg. All patients classified as having noncardiac congenital abnormali-
ties underwent evaluation by a geneticist. Cardiac diagnoses were obtained
by review of echocardiogram, cardiac catheterization, and operative re-
ports. In cases of disagreement, the diagnosis listed in the operative report
was used. Cardiac lesions were grouped according to shared anatomic and
physiologic characteristics: (1) HLHS and variants (critical systemic ven-
tricular outflow obstruction not amenable to biventricular repair), (2) tri-
cuspid atresia, (3) pulmonary atresia and variants (including pulmonary
atresia with intact ventricular septum), (4) tetralogy of Fallot (including te-
tralogy of Fallot with pulmonary atresia), and (5) other functional single
ventricle lesions with obstruction to systemic or pulmonary blood flow.
Intra- and postoperative variables related to S-PA shunt placement were
characterized, including shunt type and size, use of cardiopulmonary by-
pass, extracorporeal membrane oxygenation (ECMO) use, intravascular
volume status (as assessed by highest daily blood urea nitrogen [BUN]),
number of bloodstream or surgical wound infections, use of low-dose
(10–20 U/kg/h) heparin infusion in the immediate (48 hours) postopera-
tive period, presence of antegrade pulmonary blood flow after shunt place-
ment, duration of hospital stay, and mortality. Mortality was classified as
early (occurring  30 days of S-PA shunt placement or during the same
hospitalization) or late (>30 days after S-PA shunt placement and after dis-
charge home). Infections were defined as distinct clinical episodes requir-
ing antibiotics along with positive blood or surgical wound cultures.
During the time period of this study, low-dose heparin infusion was not
used routinely. Antiplatelet therapy was initiated postoperatively at the dis-
cretion of the attending staff. For patients requiring intervention, timing of
intervention, type of intervention, mechanism of shunt dysfunction, and use
of anticoagulant or antiplatelet therapy within the 3 days before shunt in-
tervention were recorded. The mechanism of shunt dysfunction leading
to intervention was ascertained by review of angiograms, cardiac catheter-
ization, or operative reports, and was classified as secondary to thrombosis,
mechanical distortion of the shunt or pulmonary arteries, a combination of
thrombosis and distortion, or indeterminate.
Data are reported as mean standard deviation for normally distributed
data or median (range) otherwise. Categoric data are presented as n (%).
Comparisons between the intervention and nonintervention groups using
continuous variables were performed using the Student t test for normally
distributed variables; otherwise, the Mann–WhitneyU test was used. Com-
parisons between categoric variables were performed using Fisher’s exact
or chi-square test, as appropriate. Logistic regression was also performed to
evaluate the association between identified risk factors and shunt interven-
tion. Assessments of the trend in proportions across ordered groups, used
for the analysis of shunt size and intervention rates, were made using an
extension to the Wilcoxon rank-sum test (STATA command ‘‘nptrend’’).
The association between birthweight and S-PA shunt size was assessed us-
ing Spearman’s rank correlation. Survival curves were generated using the
Kaplan–Meier method, and comparison of survival curves between the in-
tervention and nonintervention groups was performed using the log-rank
test. For the survival analysis, follow-up time was calculated from the
date of surgery to the date of death or the last date the patient was knownrdiovascular Surgery c Volume 142, Number 1 107
TABLE 1. Diagnoses (n ¼ 206)
Diagnosis No. (% of total)
Hypoplastic left heart syndrome and variants 128 (62.1)
Pulmonary atresia and variants 31 (15.0)
Tricuspid atresia 10 (4.9)
Tetralogy of Fallot 5 (2.4)
Other lesions with obstructed SBF 22 (10.7)
Other lesions with obstructed PBF 10 (4.9)
SBF, Systemic blood flow; PBF, pulmonary blood flow.
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Corporation, College Station, Tex).RESULTS
Patient Demographics
During the study period, 206 patients underwent S-PA
shunt placement at a median 3.0 days of age (0–29 days);
64.1% (132/206) were male. Cardiac diagnoses and
types of shunts placed are shown in Tables 1 and 2,
respectively. Mean birthweight was 3.0  0.6 kg, and
18.9% (39/206) had a birthweight less than 2.5 kg;
13.6% (28/206) were premature.
Noncardiac congenital abnormalities, including genetic
syndromes and heterotaxy syndrome, were identified in
21.4% (44/206) of the entire group. The most commonly
encountered specific noncardiac congenital syndromes
aside from heterotaxy included Turner syndrome (3 pa-
tients), tracheoesophageal fistula (3 patients), hemifacial
microsomia (3 patients), VACTERL association (2 pa-
tients), and trisomy 21 (2 patients). Heterotaxy syndrome
was present in 15 patients (7.3%), with 8 demonstrating
the asplenia type and 7 demonstrating the polysplenia
type of heterotaxy. Totally anomalous pulmonary venous
connection was present in 4 of the patients with heterotaxy,
with 1 demonstrating obstructed pulmonary venous connec-
tions before S-PA shunt placement.Shunt Interventions
A total of 21 S-PA shunt interventions occurred in 9.7%
of patients (20/206), with the majority (75%) being male
(Table 3). One patient underwent 2 interventions; the first
at 28 days and the second at 52 days after shunt placement.
Intervention occurred within 24 hours of S-PA shunt place-
ment in 20% (4/20); the remainder of interventions oc-
curred at a median of 12 (4–52) days after S-PA shuntTABLE 2. Types of shunts placed (n ¼ 206)
Shunt type No. (%)
mBTS 55 (26.7)
Central 5 (2.4)
Stage I palliation with mBTS 90 (43.7)
Stage I palliation with RV-PA shunt 56 (27.2)
mBTS, Modified Blalock–Taussig shunt; RV-PA, right ventricle to pulmonary artery.
108 The Journal of Thoracic and Cardiovascular Surgplacement. Surgical shunt revisions comprised 62% of in-
terventions (13/21). Cardiac catheterization was performed
in 86% of interventions (18/21) for the purposes of diagno-
sis; in the remainder, surgical shunt revision was performed
without antecedent catheterization. The mechanism of
shunt dysfunction was shunt thrombosis in 33% (7/21),
shunt distortion in 38% (8/21), a combination of thrombo-
sis and distortion in 19% (4/21), and indeterminate in 10%
(2/21) of interventions. Urgent intervention occurred in
45% of patients (9/20). The onset of shunt dysfunction
was temporally associated with cardiac arrest in 15% of pa-
tients (3/20), and ECMO was necessary in 30% of patients
(6/20).
Postoperative low-dose heparin was used in 10.2% of pa-
tients (21/206) in the entire cohort. For patients undergoing
intervention, 35% (7/20) were receiving no anticoagulant
or antiplatelet therapy within the 3 days preceding shunt in-
tervention. Infection was present in 30% of patients (6/20)
at the time of intervention. The highest BUN values mea-
sured in each of the 4 days preceding shunt intervention
were recorded and averaged for each patient; the median
of this aggregate BUN was 13.8 (3.5–43.8) mg/dL (4.9
[1.3–15.8] mmol/L).
Risk Factors for Shunt Intervention
To evaluate risk factors for early S-PA shunt intervention,
intervention, and nonintervention groups were compared
for relevant demographic and clinical variables before shunt
placement. A univariate analysis of factors associated with
shunt intervention is shown in Table 4. S-PA shunt size was
modestly correlated with weight for the entire group
(r ¼ 0.28, P<.001); there was a stronger correlation be-
tween shunt size and weight in those who received an
mBTS (r ¼ 0.65, P<.001).
In the subgroup of patients who received an mBTS
(n ¼ 145), risk factors associated with intervention were
similar to those found in the entire group. The rate of inter-
vention in the mBTS group was 7.6% (11/145). Risk factors
included trends in association with birthweight less than 2.5
kg (14.9% [20/134] in the nonintervention group with
mBTS vs 36.4% [4/11] in the intervention group with
mBTS, P ¼ .09) and in those patients with a noncardiac
congenital abnormality (20.2% [27/134] in the non-
intervention group with mBTS vs 45.5% [5/11] in the inter-
vention group with mBTS, P ¼ .07). A combined variable
representing those patients with a noncardiac congenital ab-
normality or birthweight less than 2.5 kg was significantly
associated with an intervention (OR ¼ 3.6; 95% CI,
1.4–9.2; P ¼ .009). The rate of intervention also signifi-
cantly decreased with increasing shunt size in patients
with an mBTS (P ¼ .01, Table 4). A similar analysis in
the patients who received an RV-PA shunt was limited by
the smaller sample size (n ¼ 56) and the predominant use
of a 5.0-mm shunt (88%) in this group.ery c July 2011
TABLE 3. Characteristics of patients undergoing intervention (n ¼ 20)
ID Diagnosis Heterotaxy
Shunt
procedure
Intervention
date*
Cardiac
arrest ECMO
Mode of
intervention
Cause of shunt
dysfunction
Anticoagulant/platelet
therapy within 3 days
of intervention
Patient
status
Timing of
death
1 HLHS þ S1 RV-PA 1 Surgical Distortion None Deceased Interstage
2 Truncus arteriosus, UAVC þ S1 mBTS 9 þ Transcatheter Distortion Heparin Deceased In-hospital
3 HLHS S1 RV-PA 11 Transcatheter Distortion ASA Alive
4 PA/IVS mBTS 0 Surgical Indeterminatez None Alive
5 HLHS S1 RV-PA 9 Surgical Thrombosis and distortion Heparin Deceased In-hospital
6 HLHS S1 mBTS 15 Surgical Thrombosis Heparin Deceased Post-SCPA
7 TOF mBTS 5 Transcatheter Thrombosis ASA Deceased In-hospital
8 HLHS þ S1 mBTS 11 Surgical Distortion ASA Alive
9 HLHS S1 RV-PA 46 Transcatheter Distortion ASA Alive
10 HLHS S1 RV-PA 51 Transcatheter Thrombosis and distortion ASA Deceased Interstage
11 DILV S1 Central 4 Transcatheter Thrombosis and distortion None Alive
12 HLHS S1 mBTS 18 þ þ Surgical Thrombosis and distortion Enoxaparin Deceased Post-SCPA
13 D-TGAwith IAA S1 mBTS 11 þ þ Surgical Thrombosis ASA Alive
14 HLHS S1 RV-PA 12 Transcatheter Distortion Heparin Alive
15 HLHS S1 RV-PA 17 Surgical Indeterminatex None Deceased Post-SCPA
16 HLHS S1 mBTS 0 þ þ Surgical Thrombosis None Deceased Interstage
17 HLHS S1 RV-PA 5 Surgical Distortion None Deceased In-hospital
18 HLHS þ S1 mBTS 1 þ Surgical Thrombosis None Deceased In-hospital
19y DILV S1 mBTS 28 þ Surgical Thrombosis ASA Deceased In-hospital
20 PA/IVS mBTS 13 Surgical Distortion ASA Alive
UAVC,Unbalanced atrioventricular canal; PA/IVS, pulmonary atresia with intact ventricular septum; TOF, tetralogy of Fallot;DILV, double-inlet left ventricle;D-TGA,D-loop transposition of the great vessels; IAA, interrupted aortic
arch; S1, stage I palliation; SCPA, superior cavopulmonary anastomosis; mBTS,modified Blalock-Taussig shunt; RV-PA, right ventricle to pulmonary artery; ECMO, extracorporeal membrane oxygenation; ASA, acetyl salicylic acid.
*In days after S-PA shunt placement. yUnderwent 2 interventions; data refer to the first intervention. zSuspected lability of pulmonary vascular resistance. xSuspected pulmonary overcirculation; the shunt was partially occluded with
a band.
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TABLE 4. Comparisons of patients undergoing intervention,
compared with nonintervention group for preoperative, operative,
and postoperative variables
Nonintervention
(n ¼ 186)
Intervention
(n ¼ 20)
P
value
Preoperative variables
Birthweight (kg) 3.1  0.6 2.8  0.7 .21
Birthweight<2.5 kg 33 (18) 6 (30) .18
Age at S-PA shunt (d) 3.5 (0–29) 3.0 (1–18) .23
Premature 24 (13) 4 (20) .49
Female 69 (37) 5 (25) .34
Diagnosis .43
HLHS 115 (62) 13 (65)
Pulmonary atresia 29 (16) 2 (10)
Tricuspid atresia 10 (5) 0 (0)
Obstructed SBF 18 (10) 4 (20)
Obstructed PBF 10 (5) 0 (0)
TOF 4 (2) 1 (5)
Heterotaxy syndrome 11 (6) 4 (20) .04
Congenital abnormality
(including heterotaxy)
36 (19) 8 (40) .04
Operative variables
Shunt type .27
S1 mBTS 82 (44) 8 (40)
S1 RV-PA 48 (26) 8 (40)
mBTS 52 (28) 3 (15)
Central 4 (2) 1 (5)
Shunt size (mBTS only) n ¼ 134 n ¼ 11 .03
3.0 mm 0 (0) 1 (9) .01y
3.5 mm 63 (47) 8 (73)
4.0 mm 68 (51) 2 (18)
5.0 mm 3 (2) 0 (0)
Use of CPB 18 (10) 2 (10) .99
Pulmonary arterioplasty 16 (9) 0 (0) .38
Postoperative variables
Low-dose postoperative
heparin*
20 (11) 1 (6) .35
Native PBF 21 (11) 1 (5) .70
S1, Stage I palliation; mBTS,modified Blalock–Taussig shunt; RV-PA, right ventricle
to pulmonary artery; CPB, cardiopulmonary bypass; SBF, systemic blood flow; PBF,
pulmonary blood flow; HLHS, hypoplastic left heart syndrome and variants; TOF,
tetralogy of Fallot; S-PA, systemic to pulmonary artery shunt. *Excludes 9 patients
who received ECMO during the first 48 hours after surgery. yTest for trend in an in-
crease or decrease in proportions across categories. Data are listed as median (range),
mean  standard deviation, or n (%), as appropriate.
FIGURE 1. Kaplan–Meier survival for cohort according to intervention
status. Kaplan–Meier survival curves for nonintervention (solid line) and
intervention (dashed line) groups, with number remaining at risk yearly
between 0 and 7 years after shunt placement shown at bottom. P value
shown is for comparison of overall survival between groups using log-
rank test.
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DOutcomes
The clinical characteristics and outcomes of patients
undergoing early S-PA shunt intervention are summarized
in Table 3. The in-hospital mortality was significantly
higher in the intervention group compared with the non-
intervention group (30% [6/20] vs 8.1% [15/186],
P ¼ .02). The median duration of follow-up from S-PA
shunt placement was 5.0 (0–7.0) years, with the majority
of patients having complete follow-up through September
1, 2009 (93.2% [192/206]). The survival curves were sig-
nificantly different in the patients undergoing intervention
compared with those who did not (P ¼ .002, Figure 1). At110 The Journal of Thoracic and Cardiovascular Surg1- and 5-year follow-up, median survival was 50.0%
(27.1%–69.2%) and 41.2% (19.3%–60.1%), respectively,
in the patients who required intervention compared with
83.2% (77.0–88.0%) and 76.8% (70.0–80.2%), respec-
tively, in those who did not. Of the 12 deaths in the interven-
tion group, 50% (6/12) occurred during the hospitalization
for shunt placement, 25% (3/12) occurred after hospital dis-
charge, and 25% (3/12) occurred after stage II palliation. Of
the 46 deaths in the nonintervention group, 32.6% (15/46)
occurred during the hospitalization for shunt placement,
41.3% (19/46) occurred after hospital discharge, and
26.1% (12/46) occurred after stage II palliation. Potentially
confounding factors, such as gestational age, cardiac diag-
nosis, shunt type, year of surgery, and postoperative heparin
use, were not significantly different between groups.Morbidity
Greater morbidity was observed in the intervention
group. Patients undergoing shunt intervention had a greater
incidence of bloodstream or surgical wound infections after
shunt placement (60% [12/20] vs 17.7% [33/186],
P < .001), longer median hospital length of stay (35
[6–421] days vs 16 [3–386] days, P ¼ .001 for all patients;
36 [16–134] days vs 16 [4–386] days for hospital survivors
only, P ¼ .002), and need for ECMO after shunt placement
(30% [6/20] vs 5.4% [10/186], P<.001) (Table 5).DISCUSSION
Our results demonstrate that S-PA shunt dysfunction is
a complex clinical entity with multiple potential causes,
variable clinical presentation, and significant morbidity
and mortality. In-hospital shunt intervention occurred inery c July 2011
TABLE 5. Comparisons of patients undergoing intervention,
compared with nonintervention group with respect to morbidity
after systemic-to-pulmonary artery shunt placement
Nonintervention
(n ¼ 186)
Intervention
(n ¼ 20)
P
value
Presence of infection 33 (18) 12 (60) <.001
No. of patients with
1 infection 26 (14) 3 (15) <.001
2 infections 5 (3) 4 (20)
3 infections 2 (1) 5 (25)
ECMO use 10 (5) 6 (30) <.001
Hospital length of stay (d) 16 (3–386) 35 (6–421) .001
Hospital length of stay,
hospital survivors only (d)
16 (4–386) 36 (16–134) .002
ECMO, Extracorporeal membrane oxygenation. Data are listed as median (range) or n
(%), as appropriate.
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pared with contemporary controls. Our finding of continued
late attrition in early survivors of S-PA shunt intervention
identifies this as a very high-risk subgroup of patients, as
evidenced by the fact that 50% of the deaths in the interven-
tion group died unexpectedly at home or after stage II
palliation. In addition, the intervention group also demon-
strated significantly increased measures of morbidity com-
pared with the nonintervention group, with an increased
incidence of infections, hospital length of stay, and need
for ECMO.
Risk factors for early shunt intervention included the
presence of noncardiac congenital abnormalities (including
heterotaxy syndrome) with a trend toward a higher rate of
intervention in low birthweight infants. The rate of early
shunt intervention decreased with increasing shunt size in
patients with an mBTS. Because the use of smaller size
shunts was correlated with birthweight, this may explain
the trend toward a higher rate of intervention in low birth-
weight infants. Specifically, in patients with either a low
birthweight or congenital abnormality, the risk of interven-
tion was increased significantly in patients with an mBTS.
Unfortunately, given the relatively infrequent occurrence
of early shunt intervention, our sample size precludes mul-
tivariable analysis. An association between genetic syn-
dromes and pulmonary artery hypoplasia in patients with
tetralogy of Fallot has been reported13; the higher incidence
of early shunt intervention in patients with noncardiac syn-
dromes in this study could be explained in part by anatomic
abnormalities of the pulmonary arterial circulation.
Heterotaxy is recognized to represent one of the highest-
risk subgroups of CHD.14 Patients with heterotaxy experi-
ence mortality out of proportion to other patients with
CHD.15,16 Much of the burden of mortality may be
related to obstructed pulmonary venous return,14 although
mortality may be improving in the current era for patients
with heterotaxy, both those with univentricular17 and biven-
tricular18 anatomy. In our series, despite a low incidence ofThe Journal of Thoracic and Catotally anomalous pulmonary venous connection, patients
with heterotaxy comprised approximately 20% of patients
undergoing intervention and the presence of heterotaxy
was a risk factor for early shunt intervention. Our findings
continue to provide supportive evidence that patients with
heterotaxy remain a high-risk group, even in the absence
of pulmonary venous abnormalities.
Although the study design prevented identification of in-
fection as a risk factor for intervention, the fact that 30% of
intervention patients were being treated for a culture-
positive bacterial bloodstream or surgical wound infection
at the time of intervention is notable. The link between
bacterial infections and prothrombotic states is well estab-
lished19-21; patients with S-PA shunts and intercurrent
infection warrant particularly close surveillance because
infection may cause an occult prothrombotic state,
thereby increasing the risk of shunt thrombosis.
At present, low-dose heparin is used frequently in the
postoperative period to prevent shunt dysfunction. How-
ever, during the study period, postoperative heparin prophy-
laxis was less commonly used, and we did not find
a relationship between the use of low-dose heparin infu-
sions and the incidence of shunt intervention. Our low
rate of prophylaxis combined with the low rate of interven-
tion may contribute to an inability to detect a significant as-
sociation. Other agents, such as clopidogrel, are actively
being studied for thromboprophylaxis in children with
S-PA shunts22 as additive therapy given the continued oc-
currence of shunt thrombosis with aspirin. Dehydration
may to contribute to acute shunt thrombosis; however, the
median preintervention BUN of patients, used as a marker
of intravascular volume status, was not abnormally ele-
vated. This may be related to the inpatient status of this pop-
ulation, in whom volume status and diuretic administration
were carefully monitored.
Limitations
Our study has several limitations. Although we attempted
to determine the cause of shunt malfunction by review of
catheterization and surgical reports, pathologic analysis of
the shunt was not performed, and retrospective analysis
cannot determine the cause of dysfunction with certainty.
We have likely underestimated the true incidence of shunt
thrombosis or distortion by not capturing cases that resolved
spontaneously, resolved after medical maneuvers in the
intensive care unit, occurred after hospital discharge, or re-
sulted in mortality before undergoing diagnostic testing.
RV-PA shunts placed as part of the Norwood procedure
for the palliation of HLHS may represent a different risk
profile for intervention than mBTS. In our study, the rate
of early shunt intervention was approximately twice as
high in the RV-PA shunt group compared with the mBTS
group (14.3% vs 7.6%), but this finding was not statisti-
cally significant. A larger sample size would be necessaryrdiovascular Surgery c Volume 142, Number 1 111
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Dto better understand these differences and identify risk
factors for this group because they comprised only one third
of our patient population.CONCLUSIONS
Approximately 10% of neonates undergoing S-PA shunt
placement experienced early shunt dysfunction requiring
surgical or transcatheter intervention before discharge.
Some factors, such as low birthweight, shunt size, and non-
cardiac congenital abnormalities, may help identify patients
at risk. The intervention group had a more complicated
postoperative course with greater mortality. These patients
remain at risk for late mortality; therefore, continued close
surveillance of these patients is necessary.
The authors acknowledge Susan C. Nicolson, MD, Gil Wernov-
sky,MD, Peter J. Gruber, MD, PhD, and Thomas L. Spray,MD, for
clinical care of the patients and critical review of earlier versions of
this article.References
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